Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Authors :: Jun Meng
XiaoQin Wu
Zhen Sun
RenDe Xun
MengSi Liu
Rui Hu
JianChao Huang
Source :: Frontiers in Oncology, Vol 11 (2021)
Publication Year :: 2021
Publisher :: Frontiers Media S.A., 2021.

Subjects :: chimeric antigen receptor T-cell product
CAR-T cell therapy
immunotherapy
lymphoma
leukemia
hematologic malignancy
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools